Cutaneous vasculitis after COVID‐19 vaccination in a 41‐year‐old male

Leukocytoclastic vasculitis could be a possible adverse event of different SARS‐CoV‐2 vaccines. Clinicians and manufacturers should be aware of this adverse event for appropriate diagnosis and treatment. Cutaneous vasculitis has been associated with both Coronavirus disease‐2019 (COVID‐19) and SARS‐CoV‐2 vaccines. We reported a 41‐year‐old male who developed bullous lesions and erythematous plaques leading to atrophic patches 2 weeks after injection of the second dose of the COVID‐19 vaccine. The skin biopsy showed leukocytoclastic vasculitis. The disease was self‐limited and no recurrence of symptoms happened after 6 months of follow‐up.